Molecular and Cellular Mechanisms of Chronic Myelogenous Leukemia
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 218
Special Issue Editor
Special Issue Information
Dear Colleagues,
Chronic myeloid leukemia (CML) is a hematological disorder, characterized by a chromosomal translocation between chromosomes 9 and 22 [t(9;22)], resulting in the BCR/ABL1 oncoprotein being produced.
The current treatment for CML patients in the chronic phase is to keep receiving TKI treatment, inducing a deep molecular response (DMR). Not only imatinib, but also second-generation TKI, nilotinib, and dasatinib have induced a high rate of DMR in CML patients. Such an intensive TKI treatment could induce treatment-free remission (TFR), which occurs in approximately half of all CML patients. So, CML must be a curable hematological disorder. In this process, the immunological mechanism, including cellular immune function, was considered.
In this Issue, the major role of the BCR/ABL oncoprotein for the development of CML, the mechanism of TKI treatment for CML, and the immunological involvement for TFR will be summarized.
We are looking forward to your contributions.
Dr. Yasuhiro Maeda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic myeloid leukemia
- major BCR/ABL
- TKI
- deep molecular response
- treatment free remission
